Medical device company ICU Medical (NASDAQ: ICUI) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by 8.9% year on year to $543.6 million. Its GAAP profit of $1.43 per share was significantly above analysts’ consensus estimates.

Is now the time to buy ICUI? Find out in our full research report (it’s free).

StockStory’s Take

ICU Medical’s second quarter results met Wall Street’s revenue expectations and significantly exceeded consensus profit estimates, yet the market reacted negatively. Management attributed the challenging year-over-year sales decline to the deconsolidation of the IV Solutions business and ongoing tariff headwinds. CEO Vivek Jain noted that while the consumables segment achieved record sales and the IV Systems segment saw strong demand for new installations, tariff costs and the shifting product mix weighed on results. The company’s cautious tone reflected persistent external pressures, particularly as tariffs on production in Costa Rica increased.

Looking ahead, ICU Medical’s guidance is shaped by its ongoing efforts to offset higher tariffs and drive mid-single-digit growth in its consumables and systems businesses. Management emphasized the importance of completing pending product regulatory filings and the rollout of its next-generation infusion pumps and software as key factors underpinning future performance. CFO Brian Bonnell cautioned that, although gross margin expansion from the IV Solutions joint venture is expected to continue, tariff expenses will remain a significant headwind in the coming quarters. CEO Jain added that, “Our mindset is shifting to offsetting as much of the tariff burden on the assumption that these are now permanent.”

Key Insights from Management’s Remarks

Management identified increased tariffs, a shifting product portfolio, and record consumables sales as the main factors shaping second quarter performance and forward outlook.

• Tariff impact escalates: The company faced a sharp rise in tariffs, particularly a new 15% rate on Costa Rican production, creating a significant drag on gross margins and profitability. Management indicated these expenses are now a persistent headwind, requiring mitigation through price increases and cost controls.

• Record consumables segment sales: ICU Medical achieved its highest-ever sales quarter in consumables, driven by new global customer implementations, pricing improvements, and successful 510(k) clearance for its Clave neutral displacement connectors. These connectors, supported by recent clinical studies, are positioned to drive safer patient outcomes and remain the anchor product for the segment.

• IV Systems business gains momentum: The IV Systems segment reported strong LVP (large volume pump) growth, benefiting from new installations and robust utilization rates. Management cited the early-stage rollout of the Plum Solo pump and a growing pipeline of customer RFPs as key contributors to sequential growth.

• Progress on product filings and integration: Recent 510(k) submissions for Medfusion 5000 syringe pumps and CADD ambulatory pumps mark a milestone in unifying the company’s pump portfolio under a single software platform. This strategy aims to deliver better interoperability and workflow efficiency for hospital customers.

• Portfolio optimization and cost actions: The company completed its major plant move to Costa Rica and is finalizing two additional manufacturing consolidations. These initiatives, together with the IV Solutions joint venture, are expected to streamline operations and improve future profitability, despite dilution from lower-growth segments like Vital Care.

Drivers of Future Performance

ICU Medical’s outlook is shaped by the need to manage ongoing tariff headwinds while capitalizing on product innovation and operational efficiencies.

• Tariff mitigation remains critical: Management expects tariffs to remain at elevated levels, particularly for Costa Rica-produced devices, and is focused on offsetting these costs through strategic price increases, operational efficiencies, and ongoing cost management. Any further escalation in tariffs or retaliatory trade actions remains a risk.

• Growth in consumables and systems: The company expects mid-single-digit organic growth in its consumables and IV Systems businesses, fueled by continued new product launches, expanded regulatory clearances, and customer uptake of next-generation infusion pumps and software. Management sees the replacement cycle for existing devices as a potential growth driver in the coming year.

• Manufacturing consolidation and JV benefits: Ongoing consolidation of production facilities and the recently formed IV Solutions joint venture are expected to deliver further gross margin improvements and balance sheet benefits, although the positive impact may be partly offset by tariff-related expenses.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be closely monitoring (1) the pace of regulatory approvals and customer adoption for ICU Medical’s new infusion pumps and software platforms, (2) the company’s ability to offset persistent tariff headwinds through pricing and cost actions, and (3) progress on finalizing manufacturing consolidations and optimizing the Vital Care portfolio. Execution on these fronts will be key to sustaining revenue growth and margin improvement.

ICU Medical currently trades at $112.59, down from $130.21 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.